Latest Medicine stories from Life.
At nearly 73, Dawn Zuidgeest-Craft embarks on a medical residency, challenging age norms in the field. She reflects on her journey and the dedication required to become a physician.
The Trump administration has announced measures aimed at addressing a loophole in Medicare drug price negotiations, which could affect costs for beneficiaries and pharmaceutical companies.
In an unusual initiative, Blood Cancer United, a nonprofit organization, is acquiring the last supplies of an investigational cancer drug that has been discontinued.
Recent developments in cryo-electron microscopy techniques enable the observation of materials in organic solvents, potentially transforming the study of various advanced technologies.
The landscape of obesity medications is evolving, with new drugs entering the market and peptides gaining traction in treatment protocols. The FDA's decisions will be pivotal.
In recent biotech developments, Novartis has reaffirmed its focus on molecular glue strategies amidst rising drug costs for seniors and advancements in leukemia treatments.
The dynamics of competition among Medicare Part D plans are increasingly affected by the payment structure of Medicare Advantage plans, raising concerns about fairness.
Recent developments, including a federal memo on alleged vaccine-related deaths and the establishment of a detransition clinic, illustrate how rare outcomes can shape public views on vaccine safety and gender care.
Elizabeth Selvin reflects on the stark contrast in publication fees at Nature Medicine between 2025 and 2026, highlighting a significant financial burden for researchers.
A recent analysis highlights a troubling increase in drug shortages and pricing pressures in Europe, with U.S. authorities intensifying their scrutiny.
As the U.S. observes the situation, European countries are developing varied approaches to drug pricing, which could have significant implications for the pharmaceutical sector and patient access.
Novo Nordisk expresses disappointment with a drug it previously contested with Pfizer. Meanwhile, Revolution and Tango show encouraging cancer results, and Incyte acquires a bleeding disorder treatment.
Lilly has released additional data regarding the safety and tolerability of its obesity drug retatrutide, contributing to ongoing discussions in the pharmaceutical sector.
Recent findings suggest that while Boehringer Ingelheim’s obesity drug may effectively reduce liver fat, its overall weight loss results are less compelling.
The American Diabetes Association's annual conference in New Orleans showcased new insights, including developments in hormone receptors and a monthly obesity drug.
Recent findings from a midstage study indicate that Pfizer's obesity treatment, obtained from Metsera, may be effective with monthly dosing.
The recent cancellation of medical entrance tests affecting over 2 million candidates has ignited frustration towards Prime Minister Narendra Modi's administration.
RevMed's cancer treatment appears inaccessible for certain patients, while the Supreme Court maintains an essential pathway for generic drugs amid ongoing biotech developments.
As we reflect on the six-year mark since the onset of the COVID-19 pandemic, experts are evaluating how coordinated responses to domestic violence have evolved during this challenging period.
A recent presentation on Revolution Medicines' pancreatic cancer drug garnered significant attention, earning a standing ovation. However, the broader biotech sector faced challenges this week.